Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc11.2 | Oral Communications 11: Thyroid 2 | ECE2022

What you choose makes the difference: the first medical therapy for amiodarone-induced thyrotoxicosis has significant implications on cardiovascular events and hospitalizations

Cappellani Daniele , Cosentino Giada , Morganti Riccardo , Manetti Luca , Bartalena Luigi , Bogazzi Fausto

Context: Amiodarone is a widely used anti-arrhythmic medication, however associated with a 15-20% rate of thyroid adverse effects. Amiodarone-induced thyrotoxicosis (AIT) is a complex disease due to diagnostic difficulties and therapeutic challenges. AIT patients often receive initial therapy for thyrotoxicosis before admission to a referral center. Whether the first-line medical therapy (i.e. therapies for thyrotoxicosis at first diagnosis of AIT) may affect the outcome of AI...

ea0049ep970 | Pituitary - Clinical | ECE2017

Somatostatin analogues-induced diabetes mellitus in acromegalic patients reverts after drug withdrawal: a long-term study

Cappellani Daniele , Urbani Claudio , Sardella Chiara , Marconcini Giulia , Marcocci Claudio , Rossi Giuseppe , Bogazzi Fausto

Context: Therapy with somatostatin analogues (SSAs) may have deleterious effects on glucose metabolism in patients with acromegaly, often leading to development of diabetes mellitus (DM).Aim of the study: To evaluate whether DM, which developed during therapy with SSAs, may revert after drug withdrawal and cure of acromegaly with pituitary adenomectomy.Design: Retrospective cohort study, in a tertiary referral center.<p class="...

ea0037ep1219 | Clinical Cases–Pituitary/Adrenal | ECE2015

Autoimmune hypophysitis: from pituitary expansion to empty sella: description of four cases

Marconcini Giulia , Lupi Isabella , Manetti Luca , Cosottini Mirco , Urbani Claudio , Martino Enio , Marcocci Claudio , Bogazzi Fausto

Four patients with autoimmune hypophysitis were followed since the diagnosis of the disease. All presented with severe headache, decreased libido, astenia. Case 1 and 3 presented polyuria and polydipsia. At MRI pituitary was enlarged, with high gadolinum uptake and stalk enlargement.Case 1, male 41 years. MRI volume: AP 13 mm, CC 7 mm. Hormonal assessment: central hypothyroidism, hypoadrenalism, hypogonadism, normal GH and IGF1, hyperprolactinemia, centr...

ea0070aep1065 | Hot topics (including COVID-19) | ECE2020

Efficacy and safety of long-acting pasireotide in acromegalic patients in the real life: The reappraisal of the first-dose follow-up visit

Urbani Claudio , Dassie Francesca , Zampetti Benedetta , Maria Di Certo Agostino , Cozzi Renato , Maffei Pietro , Bogazzi Fausto

Background: Pasireotide is a multi-ligand somatostatin analogue licensed in a long-acting release formulation (PAS-LAR) for the treatment of acromegaly. The real-life reports with PAS-LAR are still scanty.Objectives: To assess the efficacy and safety of PAS-LAR in patients with acromegaly.Patients and methods: Prospective observational multi-centre study enrolling acromegalics evaluated before (baseline) and 1, 6, 12, 24, and 36 mo...

ea0022p5 | Adrenal | ECE2010

Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome: a longitudinal study

Raffaelli Valentina , Manetti Luca , Ruocco Lucia , Giovannetti Clara , Genovesi Maura , Pellegrini Giovanni , Bogazzi Fausto , Martino Enio

Patients with active Cushing’s syndrome (CS) have an increased coagulability and thrombotic tendency. High glucocorticoids concentrations increase plasma clotting factors, especially von Willebrand factor (vWf) and reduced fibrinolytic capacity. Thromboemobolic complications, mainly in the postsurgical phase, have been reported.Aim of this longitudinal study was to evaluate haemostatic and fibrinolytic markers in patients with active Cushing’s ...

ea0022p606 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Impact of rosiglitazone on serum IGF1 concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study

Lombardi Martina , Rossi Giuseppe , Raggi Francesco , Urbani Claudio , Sardella Chiara , Cosci Chiara , Martino Enio , Bogazzi Fausto

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

ea0022p613 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma

Lupi Isabella , Manetti Luca , Caturegli Patrizio , Menicagli Michele , Bevilacqua Genersoso , Bogazzi Fausto , Martino Enio

Serum pituitary antibodies (Pit Abs) and tumor infiltrating lymphocytes (TILs) have been described in a small percentage of pituitary adenomas but their clinical significance remains unknown.Aim of the study was to assess Pit Abs and TILs prevalence in patients with pituitary adenomas and to determine their influence on the clinical outcome. In this prevalence case–control study were enrolled 291 pituitary adenoma cases, (110 non-secreting, 30 ACTH-...

ea0022p765 | Thyroid | ECE2010

Amiodarone-induced thyrotoxicosis in patients with multinodular goiter: type 1 or type 2 AIT?

Tomisti Luca , Dell'Unto Enrica , Brogioni Sandra , Cosci Chiara , Martino Enio , Bogazzi Fausto

Introduction: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a form of destructive thyroiditis, commonly responsive to glucocorticoids. On the contrary, type 1 AIT is an iodine-induced hyperthyroidism, occurring in patients with underlying thyroid disease often responding to thionamides.Aim of the study: To compare the effectiveness of methimazole (MMI) or prednisone (GLU) in the treatment of AIT patients with multinodular goiter with biochemical feat...

ea0014p317 | (1) | ECE2007

Different prevalence of type 1 and type 2 amiodarone-induced thyrotoxicosis over a 30-year period

Tomisti Luca , Dell’Unto Enrica , Cosci Chiara , Sardella Chiara , Bartalena Luigi , Bogazzi Fausto , Martino Enio

Amiodarone induced thyrotoxicosis (AIT) may develop in patients with either underlying thyroid disorders (type 1) or normal gland (type 2). The latter is considered a drug-induced destructive thyroditis, usually responding to glucocorticoids. Further treatments after restoring euthyroidism are often not necessary. The former is a true form of iodine-induced hyperthyroidism the management of which includes thionamides, potassium perchlorate and thyrodectomy. The prevalence of t...

ea0056p835 | Pituitary - Clinical | ECE2018

IgG4-related neuroinfundibulo-hypophysitis treated by rituximab and corticosteroids

Lupi Isabella , Urbani Claudio , Manetti Luca , Cosottini Mirco , Brancatella Alessandro , Cappellani Daniele , Bogazzi Fausto

IgG4-related hypophysitis, a type of IgG4-related disease, is a rare condition. It appears to be sensitive to glucocorticoids in most patients, but its recurrence is likely.Clinical case: A 17 year-old girl was referred for hypotonic polyuria and polydipsia of 1 month duration. Water deprivation test was suggestive of central diabetes insipidus. Basal and dynamic assessment of pituitary anterior function were unremarkable. Patient did suffer from autoimm...